India’s Innovation Leap: Biofoundry Network, Public-Private AI Research And More Actioned
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Scrip - January 28, 2026

EU-India FTA: Novel Drugs Cheaper, Will Novo Gain Edge Over Lilly?
Conclusion of India-EU talks sets ground for a free trade agreement to cut pharma tariffs, in turn lowering the cost for novel drugs like Novo’s Wegovy, though an investment protection agreement – likely influencing data exclusivity – will be concluded later.
Scrip - January 28, 2026

Otsuka’s Centanafadine Edges Closer To US Nod Following Priority Review
US priority review for Japanese firm's first-in-class ADHD drug could result in approval of a new option this year.
Scrip - January 28, 2026

Five Chinese Biotechs Tap IPOs To Study First-In-Class Candidates Overseas
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
Scrip - January 28, 2026

Insulet Leans On Manufacturing Scale And Omnipod Launches As Patch Pump Competition Broadens
While several competitors are developing or launching patch pumps, Insulet CEO McEvoy described Omnipod as differentiated by both technology and manufacturing scale. She said the company has invested roughly $3bn across R&D and manufacturing.
Medtech Insight - January 28, 2026

P&G Inspired To Expand OTC Digestive Health Lineup With Wonderbelly From Ginger Health
Wonderbelly reached market in 2022 and has notched nationwide footprint through major retailers over the years, Target stores starting in March 2023, CVS since June 2024 and Walmart since May 2025.
HBW Insight - January 28, 2026

Cipla Tackles Lanreotide Supply Woes, Solidifies India Diabetes Position
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Generics Bulletin - January 27, 2026

‘The New Default’ – Industry Gives FDA Feedback On Biosimilar Streamlining Guidance
Responding to recent FDA guidance on a new streamlined pathway for US biosimilars, off-patent industry representatives have urged the agency to make the approach “the new default” for biosimilar filings. However, PhRMA has suggested limiting the route to less complex product types.
Generics Bulletin - January 27, 2026

Sun Pharma Lines Up Generic Wegovy As India’s Obesity Drug Market Opens
Sun Pharma’s generic Wegovy product has cleared regulatory review, positioning the company to enter India’s obesity drug market once patent protection lapses.
Generics Bulletin - January 27, 2026

Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026